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Abstract
Purpose: The aim of the study was to investigate the potential of diffusion-weighted magnetic
resonance imaging (DW-MRI) and 3′-dexoy-3′-[18F]fluorothymidine ([18F]FLT) positron emission
tomography (PET) as early biomarkers of treatment response of 5-fluorouracil (5-FU) in a
syngeneic rat model of colorectal cancer liver metastases.
Procedures: Wag/Rij rats with intrahepatic syngeneic CC531 tumors were treated with 5-FU (15,
30, or 60 mg/kg in weekly intervals). Before treatment and at days 1, 3, 7, and 14 after treatment
rats underwent DW-MRI and [18F]FLT PET. Tumors were analyzed immunohistochemically for
Ki67, TK1, and ENT1 expression.
Results: 5-FU inhibited the growth of CC531 tumors in a dose-dependent manner. Immunohisto-
chemical analysis did not show significant changes in Ki67, TK1, and ENT1 expression. However,
[18F]FLT SUVmean and SUVmax were significantly increased at days 4 and 7 after treatment with 5-
FU (60 mg/kg) and returned to baseline at day 14 (SUVmax at days −1, 4, 7, and 14 was 1.1 ± 0.1,
2.3 ± 0.5, 2.3 ± 0.6, and 1.5 ± 0.4, respectively). No changes in [18F]FLT uptakewere observed in the
nontreated animals. Furthermore, the apparent diffusion coefficient (ADCmean) did not change in 5-
FU-treated rats compared to untreated rats.
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Conclusion: This study suggests that 5-FU treatment induces a flare in [18F]FLT uptake of
responsive CC531 tumors in the liver, while the ADCmean did not change significantly. Future
studies in larger groups are warranted to further investigate whether [18F]FLT PET can
discriminate between disease progression and treatment response.
Key words: 5-Fluorouracil, [18F]FLT PET, Diffusion-weighted MRI, Colorectal cancer, Response
monitoring
Introduction
During the last decade, treatment of patients with colorectal
cancer (CRC) liver metastases has significantly improved,
mainly due to improved surgical techniques, more effective
chemotherapeutic agents, and new targeted drugs [1, 2].
However, the backbone of treatment still consists of
chemotherapy with fluoropyrimidines: intravenous 5-
fluorouracil (5-FU) or oral fluoropyrimidines. These agents
are used in various combinations and schedules, such as 5-
FU in combination with leucovorin (LV), irinotecan (FOL-
FIRI), or oxaliplatin (FOLFOX), and have significantly
improved survival. Nonetheless, ultimately most patients
will develop progressive disease [3]. Currently, there are no
adequate biomarkers or early response monitoring techni-
ques that predict response to 5-FU-containing chemotherapy
schedules.
Two imaging techniques that have potential as early
imaging biomarkers for therapy response or resistance are 3′-
deoxy-3′-[18F]fluorothymidine ([18F]FLT) positron emission
tomography (PET) and diffusion-weighted magnetic reso-
nance imaging (DW-MRI). [18F]FLT is a thymidine analog,
and its uptake in tumor cells is primarily mediated by the
equilibrative nucleoside transporter 1 (ENT1) [4]. Upon
internalization, [18F]FLT is phosphorylated by thymidine
kinase (TK1) and consequently trapped in the tumor cell.
Elevated TK1 expression is observed during cell prolifera-
tion, and therefore, [18F]FLT PET is a potential marker for
tumor cell proliferation [5].
Apart from measuring tumor cell proliferation, early
response can be monitored by imaging biomarkers that
detect tumor cell death. DW-MRI measures Brownian
motion of water molecules, and the quantitative parameter
for this motion in tissue is the apparent diffusion coefficient
(ADC). Restricted diffusion, reflected by a low ADC, is
found in highly cellular tissue with intact cell membranes,
such as tumors. Less restricted diffusion, a high ADC, is
found in tissue with a low cellularity and disrupted cell
membranes, such as necrotic tissue. Therefore, DW-MRI can
potentially be used to characterize cellular integrity and
chemotherapy-induced cell death [6].
The aim of our study was to determine whether [18F]FLT
PET and DW-MRI have potential for early response monitor-
ing after cytotoxic 5-FU treatment. For that purpose, we
induced colorectal tumors in the liver of Wag/Rij rats, as an
experimental model for liver metastasis of CRC, and studied
the effect of 5-FU on tumor [18F]FLT uptake and ADC.
Material and Methods
Cell Culture and Radiolabeling
The rat colon carcinoma cell line CC531 was derived from Wag/Rij
rats exposed to 1,2-dimethyl-hydrazine and was cultured as
described previously [7, 8]. [18F]FLT was obtained from the
Department of Nuclear Medicine and PET Research, VU Univer-
sity Medical Centre, Amsterdam, The Netherlands, and was
produced as described previously [9, 10]. Radiochemical purity of
[18F]FLT exceeded 95 %. The monoclonal antibody MG1,
purchased from Antibodies for Research Applications BV (Gouda,
The Netherlands), recognizes a 80 kDa cell surface antigen on
CC531 cells and was radiolabeled with In-111 as described
previously [11, 12].
Effect of 5-FU on [18F]FLT Uptake of CC531
Cells In Vitro
CC531 tumor cells were allowed to adhere overnight in six-well
plates and were subsequently cultured in the presence of 10 μM 5-
FU for different periods of time (6–72 h). Since 5-FU is generally
administered in combination with other chemotherapeutic agents,
we also treated cells with oxaliplatin (1 μM), or 5-FU (10 μM) + oxa-
liplatin (1 μM), or 5-FU (10 μM) + oxaliplatin (1 μM) + leucovorin
(2 μM). Leucovorin enhances the effect of 5-FU by inhibiting
thymidylate synthase (TS). To measure the effect of 5-FU on
[18F]FLT uptake, 0.1 MBq of [18F]FLT was added to each well,
followed by incubation for 2 h at 37 °C in a CO2 incubator. At the
end of incubation, cells were washed once with phosphate-buffered
saline, lysed in 0.1 M NaOH, and the [18F]FLT uptake was
measured in a gamma counter. Separate wells were used to
determine the protein concentration as a measure for the number
of cells per well (BCA Protein Assay Reagent, Thermo Scientific).
Animal Experiments
Experiments were carried out in Wag/Rij rats, 6 to 8 weeks old,
obtained from Charles River Laboratories (Sulzfeld, Germany).
Experiments were carried out in female rats, unless stated
otherwise. The animals were acclimatized to laboratory conditions
for 1 week prior to experimental use and housed under nonsterile,
standard laboratory conditions (temperature, 20–24 °C; relative
humidity, 50–60 %; 12 h light/12 h dark) on sawdust in
individually ventilated cages (two or three rats per cage) with free
access to animal chow (Snif Voer, Soest, The Netherlands) and
water. All experiments were conducted in accordance with the
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principles laid out by the revised Dutch Act on Animal Exper-
imentation (WOD) and approved by the institutional Animal
Welfare Committee of the Radboud University Nijmegen. During
all experiments, general health and body weight of the rats were
monitored. CC531 tumors cells were injected subcapsularly in the
liver as described previously [13].
Dose Optimization 5-FU Therapy and SPECT/CT
with [111In]MG1
Four groups of five male Wag/Rij rats with intrahepatic CC531
tumors were treated with four cycles of 5-FU at different dose
levels (vehicle, 15, 30, or 60 mg/kg (in 0.2 ml saline)) to determine
the optimal dose that inhibits growth of CC531 tumors, without
causing severe side effects. To monitor the tumor growth of the
intrahepatic tumors noninvasively, two rats per group underwent
SPECT/CT imaging at days 5, 12, and 19 after start of treatment
(same rats per group were scanned at each time point) using In-111-
labeled MG1 antibody as a tracer to visualize tumors [14]. Three
days prior to SPECT/CT, rats were injected intravenously with
20 MBq (17–19 μg) [111In]MG1. SPECT/CT scans were acquired
with the U-SPECT-II/CT (MILabs, Utrecht, The Netherlands). Rats
were scanned under general anesthesia (isoflurane/O2) for 50 min
using the 1.0-mm diameter rat collimator tube, followed by a CT
scan (spatial resolution 160 μm, 65 kV, 615 μA) for anatomical
reference. Scans were reconstructed with MILabs reconstruction
software, using an ordered-subset expectation maximization algo-
rithm, with a voxel size of 0.75 mm. SPECT/CT scans were
analyzed, and maximum intensity projections (MIPs) were created
using the Inveon Research Workplace software (IRW, version 4.1).
At day 23, all rats were euthanized by CO2/O2 asphyxation and the
liver was examined macroscopically for tumor growth. CC531
tumors were excised and weighed. Plasma, liver, and tumor
samples of two rats from each group were collected to determine
the in vivo thymidine levels. For this, a liquid-chromatography—-
mass spectrometry (LC-MS/MS) method for the quantitative
analysis of thymidine in tumor tissue homogenate was developed
by the PK/Bioanalytics Core Facility at the CRUK Cambridge
Institute [15, 16]. The biodistribution of In-111-labeled MG1 was
determined after dissection as described previously [13].
Treatment Response Monitoring Studies
Intrahepatic liver tumors were induced in ten groups of Wag/Rij
rats (n = 7 per group). After 2 weeks, rats underwent baseline T2-
weighted and DW MRI (day −1). The next day (day 0), rats
received a single i.p. injection (5-FU at 60 or 30 mg/kg or vehicle).
At day 1, 3, or 7 after treatment, a follow-up DW-MRI was
acquired. After the DW MRI, rats were injected with [18F]FLT and
were euthanized 60 min later by CO2/O2 asphyxation. Blood,
tumor, and normal liver were collected to determine the [18F]FLT
uptake ex vivo. Tumor tissue was fixed in 4 % formaldehyde and
embedded in paraffin for immunohistochemical analysis. Rats were
excluded from the analysis if no tumor was visible on the baseline
T2-weighted image or when DWI or [18F]FLT PET acquisition
failed because of technical reasons.
To study the effect of 5-FU on [18F]FLT PET in more detail, an
additional response monitoring study was performed in two groups
of seven rats with intrahepatic liver tumors. Rats underwent a
baseline [18F]FLT PET (day −1), followed by 5-FU treatment
(60 mg/kg or vehicle) at days 0 and 7. Follow-up [18F]FLT PET
scans were acquired at days 1, 4, 7, and 14 after the first
administration of 5-FU or vehicle. After the last scan, rats were
euthanized and blood, tumor, and normal liver were collected to
determine the [18F]FLT uptake. Tumor tissue was fixed and
paraffin embedded for immunohistochemical analysis.
DW-MRI
DW-MRI was performed at 11.7T on a Bruker Biospec MR system
under Paravision 5.1 using a Bruker Mouse Body Volume Coil.
The outer diameter of the coil is 75 mm, and the inner diameter is
40 mm, which is suited to fit small rats. Anesthesia was induced
with 4 % isoflurane, and rats were maintained under anesthesia
with 2 % isoflurane; the respiratory rate of the rats was monitored
and kept constant at approximately 40 breaths/min, and temperature
was maintained at 37 °C. For morphological assessment, a T2-
weighted MR image was acquired with slices covering the whole
tumor area. The slice with the largest tumor diameter was chosen
for DW MRI. DW MRI acquisition was respiratory gated and
followed a spin-echo EPI scheme with fat suppression, TE/TR of
16/2000 ms, 4 averages, 23 segments, b-values 0, 150, 300, and
600 s/mm2, slice thickness 2 mm, FoV 5 cm, matrix 128 × 128.
ADC maps were calculated using b = 0, 150, 300, and 600 s/mm2
images. Tumor ROIs were defined manually on the b = 0 images
and then copied on the ADC maps. ADCmean, ADCmedian, and 25th
and 75th percentile values were calculated.
[18F]FLT PET
[18F]FLT PET scans were acquired using the Inveon PET/CT
system (Siemens Preclinical Solutions, Knoxville, TN) with an
intrinsic spatial resolution of 1.5 mm [17]. Rats were injected
intravenously with 10–12 MBq [18F]FLT and 50 min postinjection,
anesthesia was induced with 4 % isoflurane in air. Rats were
maintained under anesthesia with 2 % isoflurane. At 60 min
postinjection, a PET emission scan was acquired for 15 min (60–
75 min postinjection), followed by a Co-57 transmission scan of
3 min. Scans were reconstructed using the Inveon Acquisition
Workplace software (version 1.5, Siemens Preclinical Solutions),
using an ordered-set expectation maximization 3D maximum a
posteriori algorithm with the following parameters: matrix,
256 × 256 × 159; pixel size, 0.43 × 0.43 × 0.8 mm3; and β-value
of 1.5 with uniform variance. A 3D isocontour was set at 41 % of
the maximum pixel value adapted for background (normal liver) to
determine pretreatment and posttreatment SUVmean and SUVmax
[18]. To determine the SUVmax in bone marrow, a 3D volume of
interest was drawn around the left femur and subsequently, an
isocontour was set at 50 % of the maximum pixel value.
Immunohistochemistry
Antibodies against Ki67 (RM-9106-S1, Thermo Scientific), TK1
(GTX113281, Genetext), and ENT1 (ab182023, Abcam) were used
to determine expression of the respective antigens on paraffin-
embedded tumor sections (4–7 tumor sections per group). Antigen
retrieval was performed for 10 min at 99 °C in 10 mM sodium
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citrate pH 6.0 (Ki67 and TK1) or 10 mM TRIS, 1 mM EDTA,
0.05 % Tween, pH 9.0 (ENT1). Endogenous peroxidase activity
was blocked with 3 % H2O2, and nonspecific binding was blocked
by incubation with normal swine serum (Ki67 and TK1) or normal
goat serum and avidin/biotin blocking (SP-2001, Vector, ENT1).
After incubation with the primary antibody, Ki67 and TK1-stained
tumor sections were incubated with a peroxidase-conjugated
secondary antibody and ENT1-stained sections with a biotinylated
secondary antibody, followed by incubation with an avidin-biotin-
enzyme complex (Vector Laboratories, Burlingame, CA). Finally,
3,3′-diaminobenzidine (DAB) was used to develop the staining of
the tumor sections.
Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics
version 20.0 (Chicago, IL). The nonparametric, independent
samples, Kruskal-Wallis test was used to test differences in
in vitro [18F]FLT uptake and tumor load after 5-FU treatment.
Differences in ADCmean, SUVmean, and SUVmax were tested for
significance using the related-samples Wilcoxon-signed rank test or
nonrelated samples Mann-Whitney U test. All tests were two-sided,
and a p G0.05 was considered significant.
Results
5-FU Increases the Uptake of [18F]FLT of CC531
Cells In Vitro
In vitro, 5-FU (10 μM), oxaliplatin (1 μM), as well as the
combination of agents, inhibited the growth of CC531 cells
(Fig. 1a). Oxaliplatin alone significantly reduced the uptake
of [18F]FLT at 24 h (−44 ± 3.4 %) and 72 h (−79 ± 0.5 %)
after start of treatment (p = 0.024), while 5-FU alone
significantly increased [18F]FLT uptake after 24 h with
75 ± 12.2 % (p = 0.022). The 5-FU induced increase in
[18F]FLT uptake was not affected by adding oxaliplatin
(uptake increased with 62 ± 5 %, Fig. 1b).
5-FU Inhibits Growth of CC531 Liver Tumors
To determine the optimal 5-FU dose for treatment of CC531
liver tumors, four groups of Wag/Rij rats with liver tumors
were treated with vehicle, 15 mg/kg, 30 mg/kg, or 60 mg/kg
5-FU. After treatment, rats were scanned by SPECT/CT to
determine tumor load after treatment. Examples of SPECT/
CT scans acquired 19 days after the start of treatment are
presented in Fig. 2a. After four cycles of 5-FU, rats were
euthanized and tumors were excised. Macroscopic tumor
growth was absent in 5/5, 1/5, 2/5, and 0/5 rats treated with
60 mg/kg, 30 mg/kg, 15 mg/kg 5-FU, and vehicle only,
respectively. The mean weights of macroscopically visible
tumors are presented in Fig. 2b and the ex vivo biodistribu-
tion of [111In]MG1 is presented in Fig. 2c. Tumor load was
significantly decreased in the 30 and 60 mg/kg groups,
compared to the rats that received vehicle only (p G 0.012).
Thymidine levels in plasma and liver decreased with
increasing doses of 5-FU, while there was no major decrease
in tumor thymidine levels (Fig. 3). In the 60 mg/kg group,
no residual tumor tissue was left to analyze thymidine levels.
Immunohistochemical Analysis of CC531 Liver
Tumors
CC531 tumor sections were analyzed for necrosis, Ki67, TK1,
and ENT1 expression. Representative images of 5-FU-treated
tumors are presented in Fig. 4. HE staining showed an increase
in necrotic areas in both control and 5-FU-treated tumors. The
percentage of Ki67 positive tumor cells did not change during
treatment and was 86 ± 7, 92 ± 4, 90 ± 4, 89 ± 5, and 78 ± 4 %,
for tumors at days −1, 1, 3, 7, and 14 post-5-FU treatment,
respectively. TK1 and ENT1 staining did not show obvious
changes between vehicle and 5-FU-treated rats.
5-FU Treatment Induces a Flare of [18F]FLT
Uptake in CC531 Liver Tumors
While conventional immunohistochemical biomarkers did
not correlate with 5-FU treatment response, [18F]FLT uptake
Fig. 1. a Protein concentration of CC531 cell lysates and b [18F]FLT uptake of CC531 cells cultured with 5-FU (10 μM),
oxaliplatin (Ox, 1 μM), or a combination of 5-FU with Ox with or without leucovorin (L, 2 μM). Uptake was measured as
percentage of the added radioactivity per milligram cell protein.
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in CC531 tumors increased significantly during 5-FU
therapy. Biodistribution studies showed that tumor uptake
of [18F]FLT increased at days 3 and 7 after treatment with
60 mg/kg 5-FU (p = 0.017 and 0.026, respectively),
compared with [18F]FLT tumor uptake measured at the
same time point in the control group (Fig. 5). There was no
clear increase in [18F]FLT uptake in the 30 mg/kg group. At
day 7, [18F]FLT tumor uptake did significantly differ
compared with untreated tumors (p = 0.038). This could be
explained by one single outlier in this group.
In a separate group of animals (n = 7), intrahepatic tumors were
monitored longitudinally with [18F]FLT PET. In six out of
seven rats, a more than 2-fold increase in [18F]FLT SUVmax
was observed at day 4 or 7 posttreatment, while for one out of
seven rats, the maximum increase in [18F]FLT SUVmax was
obtained at day 14 posttreatment (1.6-fold increase). Figure 6a
shows typical examples of [18F]FLT PET scans of a 5-FU-
treated rat and vehicle-treated rat. Quantification of [18F]FLT
scans (Fig. 6b, c) showed that the SUVmean (data not shown)
and SUVmax were increased at days 4 and 7 after 60 mg/kg 5-
FU. SUVmax at baseline, and 4, 7, and 14 days after treatment
was 1.05 ± 0.12, 2.31 ± 0.54, 2.28 ± 0.60, and 1.51 ± 0.42,
respectively (p = 0.002). In the control group, SUVmean and
SUVmax did not change significantly. The [
18F]FLT uptake in
bone marrow was significantly decreased after 5-FU treatment
(p = 0.004) and was not affected in the vehicle group.
5-FU Treatment Does not Cause Changes in the
ADC of CC531 Liver Tumors
The pretreatment and posttreatment ADCmedian values are
depicted in Fig. 7 and Table 1. The ADC seems to increase
slightly at day 1 after 60 mg/kg 5-FU. However, the change in
ADCmedian, ADCmean, and 75th and 25th percentiles in 5-FU-
treated groups was not significantly different compared to the
change in vehicle-treated groups. There was no correlation
between the change in ADCmedian and [
18F]FLT uptake.
Fig. 2. a Representative SPECT/CT images of rats with CC531 tumors, acquired at day 19 after start of 5-FU treatment. b
CC531 tumor load after four cycles of 5-FU treatment as measured after dissection of the tumors presented as mean ± SD
(n = 5 per group). c Biodistribution of [111In]MG1 after dissection presented as mean ± SD (n = 5 per group).
Fig. 3. Thymidine levels in plasma, liver, and tumor as
measured by LC-MS. Rats treated with 60 mg/kg 5-FU did
not have any residual tumor to analyze tumor thymidine
levels.
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Discussion
The aim of this study was to evaluate whether the observed
therapeutic effect of 5-FU could be monitored with DW-
MRI and [18F]FLT PET in a syngeneic rat model of CC531
liver tumors. It seems that 5-FU did not induce significant
changes in ADCmedian compared with vehicle-treated rats. In
contrast, a flare effect was observed for [18F]FLT PET at
days 3 to 7 after start of treatment. At later time points,
[18F]FLT uptake seemed to return to baseline.
DW-MRI can be used to characterize cellular integrity and
chemotherapy-induced cell death [6]. Early 5-FU therapy
effects can induce cell swelling, resulting in a decreased
ADC, while at later time points, apoptosis and necrosis can
occur, resulting in an increased ADC. In CC531 liver tumors,
we did not observe an increase in ADC during 5-FU treatment.
Fig. 4. Immunohistochemical analysis of CC531 liver tumors treated with 60 mg/kg 5-FU. Magnification: HE and ENT1 ×400,
Ki67 and TK1 ×200.
Fig. 5. Uptake of [18F]FLT in CC531 tumors after 5-FU treatment (mean ± SD). Uptake was measured after dissection of the
tumors. Asterisks indicate a significant difference in the mean [18F]FLT uptake in 5-FU-treated tumors compared with the
vehicle-treated tumors at the same time point. The symbols represent the individual rats.
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Potentially, the ADC changes at days 3 and 7 could have been
masked by cellular swelling early after start of therapy. Tumor
necrosis was analyzed immunohistochemically. The increase
in necrosis did not differ between 5-FU-treated and control
tumors. Other factors which correlate to ADC which warrant
future research are cell density, extracellular space, and
nuclear-to-cytoplasmic ratio [6]. A few clinical studies have
shown an increase in ADC upon arterial infusion of 5-FU or
chemoradiation [19–21]. These ADC measurements were
performed in patients treated for at least 1 week or longer with
5-FU, while in our study, rats were only measured up to 7 days
posttreatment. In addition, most clinical studies were per-
formed in patients receiving chemoradiation, and this combi-
nation may have a more pronounced effect on tumor ADC than
5-FU alone.
In this study, we observed a significant increase in
[18F]FLT during 5-FU treatment. In clinical practice, 5-FU
is frequently administered in combination with oxaliplatin.
In vitro, we have shown that the addition of oxaliplatin did
not affect the [18F]FLT flare. The uptake of [18F]FLT has
been linked to cellular proliferation; however, [18F]FLT is
not incorporated into the DNA [10]. Its accumulation
depends on activity of the ENT1 transporter, the rate of
phosphorylation by TK1, and the level of endogenous
thymidine [15, 22, 23]. Therefore, [18F]FLT uptake does
not necessarily reflect tumor cell proliferation. For example,
drugs that inhibit the de novo pathway of DNA synthesis
can alter the activity of TK1, and thus that of [18F]FLT
phosphorylation and its trapping in the tumor cell [24]. 5-FU
is an antimetabolite that inhibits thymidylate synthase (TS),
Fig. 6. a Representative [18F]FLT PET scans of rats treated with vehicle or 60 mg/kg 5-FU. Tumors are indicated by the red
arrows. The [18F]FLT uptake was quantified for b tumor and c femur. The lines represent individual rats.
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which is a critical enzyme in the de novo synthesis of
thymidine. As a consequence, tumor cells can upregulate the
thymidine salvage pathway, resulting in increased TK1
activity and redistribution of ENT1 to the cell surface,
which leads to enhanced [18F]FLT uptake and trapping in
the tumor cell. Here, we indeed observed a flare in [18F]FLT
uptake after 5-FU treatment. A potential explanation might
be an increase in TK1 and ENT1 expression and/or activity
induced by 5-FU treatment. Immunohistochemical analysis
of our tumor samples did not show a clear upregulation of
TK1 or ENT1 expression. However, it must be noted that
differences in enzyme activity or distribution at the cell
surface cannot be assessed by these immunohistochemical
analyses. Literature reports contrasting information regard-
ing TK1 and ENT1. Some studies describe an increase in
TK1 activity and redistribution of ENT1 to the cell
membrane, while others show that 5-FU does not alter
TK1 and/or ENT1 expression or activity [23–31]. Another
possible explanation for the increase in [18F]FLT uptake
might be changes in the level of endogenous thymidine. We
observed decreased levels of endogenous thymidine levels in
plasma and liver after 4 weeks of 5-FU treatment.
Endogenous thymidine and [18F]FLT compete for tumor
cell uptake via ENT1 and phosphorylation by TK1 [23, 32].
However, further research is needed to assess whether this
indeed caused the flare of [18F]FLT uptake at earlier time
points after start of treatment. Overall, our data indicate that
[18F]FLT uptake does not solely reflect tumor cell prolifer-
ation but that the pathway responsible for [18F]FLT uptake is
more complex.
A few clinical studies have assessed the role of [18F]FLT
PET for early response monitoring during 5-FU-containing
treatment regimens. In two studies, patients with rectal
cancer were scanned before and 2 weeks after chemo-
radiation. [18F]FLT uptake decreased significantly, but did
not correlate to histopathological tumor regression [33, 34].
However, a strong decrease in [18F]FLT uptake (decrease in
SUVmax ≥ 60 %) was associated with prolonged disease-free
survival [34]. Hong et al. analyzed [18F]FLT uptake 1 and
3 days after 5-FU infusion in a FOLFOX-treatment regimen.
[18F]FLT flare 1 day after 5-FU administrationwas related to poor
treatment response as assessed by CT. Three days after treatment,
[18F]FLT uptake was significantly decreased in responders, while
it was not different from the baseline scan in nonresponders. This
study excluded liver metastases from analysis [35].
In the current study, we found a flare in [18F]FLT uptake
in 5-FU responsive liver CC531 liver tumors in rats. This is
in contrast with the abovementioned studies. However, it
must be noted that none of these studies included liver
metastases in their analysis. In clinical studies, [18F]FLT
PET imaging of hepatic metastases is hampered by the
increased retention of [18F]FLT in the liver, reducing the
sensitivity. In addition, timing of [18F]FLT follow-up scan
appears of crucial importance to measure the flare effect. In
human xenografts in mice, it has been reported that
[18F]FLT flare was detectable as early as 1 h to 1 day
posttreatment, while in our experiments, this was detectable
4 to 7 days posttreatment [24, 25, 29]. The only clinical
study that included measurements 1 to 3 days after 5-FU
treatment indeed showed an increase in [18F]FLT uptake,
although this was associated with a poor response instead of
good response [35].
Fig. 7. Difference in ADCmean of CC531 tumors treated with vehicle or 5-FU, compared with pretreatment scan. The symbols
represent the individual rats.
Table 1. ADCmedian of CC531 tumors treated with vehicle or 5-FU
Treatment ADCmedian (×10
−3 mm2/s)
Baseline Posttreatment
Vehicle
Day 1 1.18 ± 0.40 1.17 ± 0.35
Day 3 1.74 ± 0.51 1.64 ± 0.38
Day 7 1.59 ± 0.84 1.19 ± 0.11
5-FU (30 mg/kg)
Day 1 1.38 ± 0.55 1.15 ± 0.36
Day 3 1.37 ± 0.45 1.18 ± 0.55
Day 7 1.40 ± 0.53 1.04 ± 0.38
5-FU (60 mg/kg)
Day 1 1.47 ± 0.37 2.11 ± 0.96
Day 3 1.55 ± 1.04 1.57 ± 0.74
Day 7 1.13 ± 0.42 1.51 ± 0.60
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In contrast to the increased [18F]FLT uptake in CC531
tumors, a decrease in [18F]FLT uptake was observed in bone
marrow of 5-FU-treated rats. [18F]FLT uptake in bone
marrow is caused by high proliferative activity of hema-
topietic cells. Chemotherapeutic drugs inhibit the prolifera-
tion of these cells and may thus reduce the [18F]FLT uptake.
In our model, we showed that 5-FU has differential effects
on proliferating bone marrow cells compared with CC531
tumor cells. To our knowledge, there are only few studies
that report on [18F]FLT uptake in bone marrow after
treatment with TS inhibitors. One study in breast cancer
patients treated with pemetrexed showed enhanced [18F]FLT
bone marrow uptake 4 h after treatment, while tumor uptake
did not change [36]. Thus, the flare in [18F]FLT uptake in
bone marrow might occur at earlier time points then
measured in our study. Other studies with TS inhibitors
have also reported differential effects on [18F]FLT uptake in
tumor and normal proliferating tissues, suggesting that bone
marrow may respond differently to TS inhibitors than tumor
cells [37]. Future research is warranted to investigate the role
of TK1 and ENT1 in this.
This study suggests that 5-FU does not affect ADC but
induces a flare in [18F]FLT uptake in CC531 liver tumors.
However, several limitations should be taken into account
when interpreting these data. First of all, the reproducibility
of the ADC and [18F]FLT measurements in this specific
model is unknown and this should be addressed in future
studies. Second, some of the experimental groups in the
study consisted of a small number of animals (three to seven
rats per group). Several rats had to be excluded from the
study because of lack of intrahepatic tumor growth. Finally,
ADC measurements in rat liver are very sensitive to motion
artifacts due to breathing of the animal. Although respiratory
gating was applied, this might still have had a negative
impact on image quality.
Conclusion
This study suggests that 5-FU treatment induces a flare in
[18F]FLT uptake of responsive CC531 tumors in the liver,
while the ADC did not change significantly. An increase in
[18F]FLT PET uptake might predict response to treatment,
although accurate timing is crucial to identify and measure
the [18F]FLT flare effect. Additional studies in larger groups
are warranted to investigate the reproducibility of the
[18F]FLT and ADC measurements in this model. Further-
more, it remains to be determined whether [18F]FLT PET
can discriminate between disease progression and treatment
response in preclinical cancer models. Finally, studies in
colorectal cancer patients with liver metastasis are war-
ranted, to determine whether this flare effect can also be
measured in patients treated with 5-FU.
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